Abstract

BackgroundPatients with inflammatory bowel disease (IBD) experience depression, even in the remission phase of IBD symptoms. Although mapping depression-associated brain regions through the gut-brain axis can contribute to understanding the process, the mechanisms remain unclear. Our previous results support the idea that glutamatergic transmission in the ventrolateral periaqueductal gray (vlPAG) mediates stress-induced depression-like behaviors. Thus, we hypothesize that the vlPAG plays a role in regulating depression during remission of IBD.MethodsWe used dextran sulfate sodium (DSS)-induced visceral pain model to evoke depression-like behaviors, assessed by tail suspension test (TST) and sucrose preference test (SPT), and electrophysiological recordings from vlPAG.ResultsSymptoms of animals modeling IBD were relieved by replacing DSS solution with normal drinking water, but their depression-like behaviors sustained. Moreover, the impairment of glutamatergic neurotransmission in vlPAG was sustained as well. Pharmacologically, microinfusion of the glutamate receptor 1 (GluR1) antagonist NASPM into vlPAG mimicked the depression-like behaviors. Furthermore, intra-vlPAG application of AMPA and AMPA receptor-mediated antidepressant (2R,6R)-hydroxynorketamine [(2R,6R)-HNK] reversed the DSS-induced depression-like behaviors in the remission phase of visceral abnormalities.ConclusionOur results suggest that vlPAG glutamatergic transmission mediates depression-like behaviors during remission of DSS-induced visceral pain, suggesting that vlPAG mapping to the gut-brain axis contributes to depression during remission of IBD.

Highlights

  • ReagentsDextran sulfate sodium (#160110; MP Biomedicals), (-) bicuculline methiodide (#2503; Tocris Bioscience), tetrodotoxin (TTX, #1069), (RS)-α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) (#0169; Tocris Bioscience), (2R,6R)HNK hydrochloride (#6094; Tocris Bioscience), and 1-naphthyl acetyl spermine trihydrochloride (NASPM; #2766, Tocris Bioscience) dissolved in water or dimethyl sulfoxide (DMSO) were used in the study

  • We found that dextran sulfate sodium (DSS) treatment dramatically decreased the abdominal withdrawal threshold (Figure 1G, Time: F3,27 = 26.82, p < 0.0001; Treatment: F1,9 = 35.81, p = 0.0002; Interaction: F3,27 = 30.95, p < 0.0001; n = 10 in each group, repeated measure two-way analysis of variance (ANOVA)) and enhanced Colorectal distension (CRD)-induced visceral motor response (VMR) (Figures 1H,I, Time: F3,54 = 26.27, p < 0.0001; Stimuli intensity: F2,18 = 43.95, p < 0.0001; Interaction: F6,54 = 0.07832, p = 0.998; n = 7 in each group, repeated measure two-way ANOVA) on day 7, and no significant differences were observed after the recovery on days 14 or 21 (Figures 1G–I)

  • We examined whether postsynaptic mechanisms contributed to the impairments and found that AMPA-mediated currents in the ventrolateral periaqueductal gray (vlPAG) were depressed in both the DSS and DSS + water groups (Figure 3F, F2,14 = 17.62, p = 0.0002; Con: n = 5; DSS: n = 5; DSS + water: n = 7, one-way ANOVA)

Read more

Summary

Introduction

ReagentsDextran sulfate sodium (#160110; MP Biomedicals), (-) bicuculline methiodide (#2503; Tocris Bioscience), tetrodotoxin (TTX, #1069), (RS)-AMPA (#0169; Tocris Bioscience), (2R,6R)HNK hydrochloride (#6094; Tocris Bioscience), and 1-naphthyl acetyl spermine trihydrochloride (NASPM; #2766, Tocris Bioscience) dissolved in water or dimethyl sulfoxide (DMSO) were used in the study. The final concentrations of DMSO were controlled to be less than 0.1% in water. The symptoms of IBD are long-lasting and often combined with other psychological mood disorders, including depression and anxiety (Regueiro et al, 2017; Bruce-Keller et al, 2018; Gracie et al, 2018). Patients in the remission phase of IBD have high prevalence of anxiety and depression (Simren et al, 2002; Abautret-Daly et al, 2018; Gracie et al, 2018). Patients with inflammatory bowel disease (IBD) experience depression, even in the remission phase of IBD symptoms. We hypothesize that the vlPAG plays a role in regulating depression during remission of IBD

Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call